Regulatory Story

RNS Number : 9623N
Shield Therapeutics PLC
15 August 2017
 

 

 

Shield Therapeutics plc

 

("Shield" or the "Group")

 

Notice of Results

 

London, UK, 15 August 2017: Shield Therapeutics (LSE: STX), a specialty pharmaceutical company focused on secondary care, announces it will report its interim results for the six months ended 30 June 2017 on Wednesday 20 September 2017.

 

Shield will host a presentation and conference call for analysts at 9.30am BST on the morning of the results in the Guildhall Room at 85 Gresham Street, London, EC2V 7NQ.

- Ends -

For further information please contact:

Shield Therapeutics plc

+44 (0)20 7186 8500 

Carl Sterritt, Chief Executive Officer

Joanne Estell, Chief Financial Officer

Karl Keegan, Director Corporate Development


 

Nominated Adviser and Joint Broker


 

+44 (0)20 3100 2222

Liberum Capital Limited


Christopher Britton

Steve Pearce

Jonathan Wilkes-Green

 

Joint Broker


+44 (0)20 7418 8900

Peel Hunt LLP



James Steel

Alastair Rae

Oliver Jackson



Financial PR Advisor

+44 (0) 203 709 5700

Consilium Strategic Communications


Mary-Jane Elliott

Matthew Neal


 

 

About Shield Therapeutics plc

Shield Therapeutics is a specialty pharmaceutical company focused on the commercialisation and development of late-stage, hospital-focused pharmaceuticals which address areas of unmet medical need.  Our clear purpose is to help our patients become people again, by enabling them to enjoy the things that make the difference in their everyday lives.  The Group has a marketed product, Feraccru®, for the treatment of iron deficiency anaemia (IDA) in adult patients with inflammatory bowel disease (IBD) which has exclusive IP rights until the mid-2030's. In addition, the Group is developing PT20, a late-stage pharmaceutical for the treatment of systemic phosphate accumulation (hyperphosphatemia). Shield Therapeutics, headquartered in London, is listed on LSE's AIM under the ticker STX. For more information please visit www.shieldtx.com

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NORBUGDIIXBBGRS